Complete Atrioventricular Septal Defect Repair in Patients With Down Syndrome Presenting Beyond Six Months- A Single

Kartik Patel1, Chandrasekaran Ananthanarayanan1, Trushar Gajjar1

  • 1Department of Cardiovascular and Thoracic Surgery, U. N. Mehta Institute of Cardiology and Research Centre, Ahmedabad, India.

Insights

Complete atrioventricular septal defect repair in Down syndrome patients over six months old is feasible. Despite early mortality risks, long-term survival is 85%, with careful monitoring for valve issues crucial.

Area of Science:

  • Cardiology
  • Pediatric Surgery
  • Genetics

Background:

  • Complete atrioventricular septal defect (cAVSD) is the most common cardiac defect in Down syndrome (DS).
  • Early surgical repair (before 6 months) is recommended to prevent pulmonary artery hypertension (PAH).
  • Delayed repair is common in developing countries, necessitating outcome analysis.

Purpose of the Study:

  • To retrospectively analyze the outcomes of biventricular repair for cAVSD in DS patients presenting after six months of age.
  • To identify risk factors for mortality and reoperation in this cohort.
  • To evaluate long-term survival and clinical status post-repair.

Main Methods:

  • Retrospective review of 60 DS patients with cAVSD undergoing biventricular repair (2015-2019) after 6 months of age.
  • Comparison with 42 DS patients repaired before 6 months.
  • Analysis of laboratory parameters, echocardiographic data, clinical findings, and follow-up results.

Main Results:

  • Median age at repair was 8 months; 11.7% early mortality (n=7) due to RV dysfunction/PAH and sepsis.
  • Independent risk factors for mortality included right AVVR grade, postoperative bilirubin, and creatinine.
  • Mean follow-up was 1658 days, with an 85% survival rate at 1, 5, and 10 years; late reoperation rate was 5.6%.

Conclusions:

  • Surgical repair of cAVSD in late-presenting DS patients is feasible with good long-term outcomes.
  • Close follow-up is essential to monitor for potential late development of right atrioventricular valve regurgitation (AVVR).
  • Patients remain asymptomatic with no residual severe PAH at long-term follow-up.

Related Concept Videos

Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753